I agree Fouremm 100% that someone with much much greater BP experience at a senior level would have a much easier time to get a proper valuation for both RVX and Zenith.  Unfortunately, ego and $2 million compensation for both companies is hard to walk away from , plus Zenith and RVX has a few insider happy to accumulate their ownership position at a fraction of what both companies would be worth with a properly managed company on th Nasdaq, Its an absolute joke that a company with such high science promise with a BTD is trading at penny stock status. The only thing keeping me invested is my belief at some point a BP will take a stab at a major partnership with either Zenith , RVX or both, based on either the potential postive  covid results or very strong interest in the BOM2 trial, Great Zenith new so far!!